MedTrace Logo

Sugammadex/Neostigmine and Liver Transplantation

NCT02697929 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-21

No results posted yet for this study

Summary

Cirrhotic patients undergoing liver transplantation are at very high risk of post operative complication such as post-operative residual curarization.

Rocuronium is a neuromuscular blocking agent that nowadays can be safely and rapidly antagonized with sugammadex.

No one study compared sugammadex versus neostigmine after rocuronium infusion during liver transplantation.

Conditions

  • Postoperative Residual Curarization
  • Liver Transplantation

Interventions

DRUG

sugammadex

DRUG

Neostigmine

Sponsors & Collaborators

  • Azienda Ospedaliera S. Maria della Misericordia

    lead OTHER

Principal Investigators

  • livia pompei, MD · AOU Santa Maria Della Misercordia

  • giorgio della rocca, FP, MD · AOU Santa Maria Della Misercordia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02697929 on ClinicalTrials.gov